XML 27 R15.htm IDEA: XBRL DOCUMENT

Management and Director Compensation	6 Months Ended
Jun. 30, 2022
Management And Director Compensation
Management and Director Compensation	Note 9 – Management and Director Compensation The Company paid its officers cash compensation totaling $240,000 and $25,000 and $510,000 and $125,927 for the three and six month periods ended June 30, 2022 and 2021, respectively. Of these amounts attributable to the Company’s CEO, $110,000 was paid to Advanomics Corporation (now known as TRT Pharma Inc.), a company controlled by the CEO of the Company. In addition, the Company issued 300,000 shares of common stock valued at $918,000 to its officers during the three months ended June 30, 2021. The value of these shares was based upon the closing price of the Company’s common stock of $3.06 on the issuance date. The Company paid its directors cash compensation totaling $50,000 and $-0- for the three and six month periods ended June 30, 2022 and 2021, respectively.

Management and Director Compensation

6 Months Ended

Jun. 30, 2022

Management And Director Compensation

Note 9 – Management and Director Compensation

The Company paid its officers cash compensation totaling $240,000 and $25,000 and $510,000 and $125,927 for the three and six month periods ended June 30, 2022 and 2021, respectively. Of these amounts attributable to the Company’s CEO, $110,000 was paid to Advanomics Corporation (now known as TRT Pharma Inc.), a company controlled by the CEO of the Company. In addition, the Company issued 300,000 shares of common stock valued at $918,000 to its officers during the three months ended June 30, 2021. The value of these shares was based upon the closing price of the Company’s common stock of $3.06 on the issuance date.

The Company paid its directors cash compensation totaling $50,000 and $-0- for the three and six month periods ended June 30, 2022 and 2021, respectively.